Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

DLBCL

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • NL-Rotterdam-ERASMUSMC, Rotterdam, Netherlands

Study leads
  • P.J. Lugtenburg, Dr.

    Principal Investigator

    NL-Rotterdam-ErasmusMC